Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-1: First-in-Human Study of Repotrectinib (TPX-0005) in Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Rearrangements
2016-003616-13Phase 2Active
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of repotrectinib in Nonhematologic neoplasms, central nervous system tumor and cancer, sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Safety and tolerability of repotrectinib, Pharmacokinetics of repotrectinib and 4 more. Started Aug 2019; status: active.
02
Drugs
repotrectinib
03
Conditions
Nonhematologic neoplasmscentral nervous system tumorcancer
Beyond the preview
Go deeper on 2016-003616-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003616-13.